Neuronal and vascular oxidative stress in Alzheimer's disease

Current Neuropharmacology

Volumn 9, Issue 4, 2011, Pages 662-673

  Massaad, Cynthia A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Axonal transport; Blood flow; Learning; Memory; Oxidative stress; Reactive oxygen species

Indexed keywords

AMYLOID BETA PROTEIN; ANTIOXIDANT; COPPER ZINC SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TAU PROTEIN;

ALZHEIMER DISEASE; BLOOD FLOW; BLOOD VESSEL; HUMAN; LEARNING; MEMORY; NERVE DEGENERATION; NERVE FIBER; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 82955216246     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911798376244     Document Type: Review

References (191)

1. Alzheimer's disease facts and figures. Alzheimers Dement., 2009, 5(3), 234-270.
2. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
3. Grundke-Iqbal, I.; Iqbal, K.; Tung, Y. C.; Quinlan, M.; Wisniewski, H. M.; Binder, L. I. Abnormal phosphorylation of the microtubuleassociated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A., 1986, 83(13), 4913-4917.
4. Chow, V. W.; Mattson, M. P.; Wong, P. C.; Gleichmann, M. An overview of APP processing enzymes and products. Neurmol. Med., 2010, 12(1), 1-12.
5. Selkoe, D. J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N.Y. Acad. Sci., 2000, 924, 17-25.
6. de la Torre, J. C. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol., 2004, 3(3), 184-190.
7. Hensley, K.; Hall, N.; Subramaniam, R.; Cole, P.; Harris, M.; Aksenov, M.; Aksenova, M.; Gabbita, S. P.; Wu, J. F.; Carney, J. M. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem., 1995, 65(5), 2146-2156.
8. Markesbery, W. R.; Lovell, M. A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging, 1998, 19(1), 33-36.
9. Pappolla, M. A.; Omar, R. A.; Kim, K. S.; Robakis, N. K. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am. J. Pathol., 1992, 140(3), 621-628.
10. Smith, C. D.; Carney, J. M.; Starke-Reed, P. E.; Oliver, C. N.; Stadtman, E. R.; Floyd, R. A.; Markesbery, W. R. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A., 1991, 88(23), 10540-10543.
11. Smith, M. A.; Richey Harris, P. L.; Sayre, L. M.; Beckman, J. S.; Perry, G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci., 1997, 17(8), 2653-2657.
12. Anantharaman, M.; Tangpong, J.; Keller, J. N.; Murphy, M. P.; Markesbery, W. R.; Kiningham, K. K.; St Clair, D. K. Betaamyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS 1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am. J. Pathol., 2006, 168(5), 1608-1618.
13. Anandatheerthavarada, H. K.; Biswas, G.; Robin, M. A.; Avadhani, N. G. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J. Cell Biol., 2003, 161(1), 41-54.
14. Manczak, M.; Park, B. S.; Jung, Y.; Reddy, P. H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromol. Med., 2004, 5(2), 147-162.
15. Lovell, M. A.; Robertson, J. D.; Teesdale, W. J.; Campbell, J. L.; Markesbery, W. R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci., 1998, 158(1), 47-52.
16. Nair, N. G.; Perry, G.; Smith, M. A.; Reddy, V. P. NMR studies of zinc, copper, and iron binding to histidine, the principal metal ion complexing site of amyloid-beta peptide. J. Alzheimers Dis., 2010, 20(1), 57-66.
17. Curtain, C. C.; Ali, F.; Volitakis, I.; Cherny, R. A.; Norton, R. S.; Beyreuther, K.; Barrow, C. J.; Masters, C. L.; Bush, A. I.; Barnham, K. J. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem., 2001, 276(23), 20466-20473.
18. Dong, J.; Atwood, C. S.; Anderson, V. E.; Siedlak, S. L.; Smith, M. A.; Perry, G.; Carey, P. R. Metal binding and oxidation of amyloidbeta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry, 2003, 42(10), 2768-2773.
19. 2. J. Biol. Chem., 2002, 277(43), 40302-40308.
20. Huang, X.; Atwood, C. S.; Hartshorn, M. A.; Multhaup, G.; Goldstein, L. E.; Scarpa, R. C.; Cuajungco, M. P.; Gray, D. N.; Lim, J.; Moir, R. D.; Tanzi, R. E.; Bush, A. I. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry, 1999, 38(24), 7609-7616.
21. Mecocci, P.; MacGarvey, U.; Beal, M. F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol., 1994, 36(5), 747-751.
22. Matsuoka, Y.; Picciano, M.; La Francois, J.; Duff, K. Fibrillar betaamyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience, 2001, 104(3), 609-613.
23. Lovell, M. A.; Ehmann, W. D.; Butler, S. M.; Markesbery, W. R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology, 1995, 45(8), 1594-1601.
24. Smith, M. A.; Taneda, S.; Richey, P. L.; Miyata, S.; Yan, S. D.; Stern, D.; Sayre, L. M.; Monnier, V. M.; Perry, G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. U.S.A., 1994, 91(12), 5710-5714.
25. Smith, M. A.; Rottkamp, C. A.; Nunomura, A.; Raina, A. K.; Perry, G. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta, 2000, 1502(1), 139-144.
26. Tarozzi, A.; Morroni, F.; Merlicco, A.; Bolondi, C.; Teti, G.; Falconi, M.; Cantelli-Forti, G.; Hrelia, P. Neuroprotective effects of cyanidin 3-O-glucopyranoside on amyloid beta (25-35) oligomerinduced toxicity. Neurosci. Lett., 2010, 473(2), 72-6.
27. Massaad, C. A.; Washington, T. M.; Pautler, R. G.; Klann, E. Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A., 2009, 106(32), 13576-13581.
28. Dumont, M.; Wille, E.; Stack, C.; Calingasan, N. Y.; Beal, M. F.; Lin, M. T. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J., 2009, 23(8), 2459-2466.
29. Hashimoto, M.; Katakura, M.; Hossain, S.; Rahman, A.; Shimada, T.; Shido, O. Docosahexaenoic acid withstands the Abeta(25-35) induced neurotoxicity in SH-SY5Y cells. J. Nutr. Biochem., 2010, 22(1), 22-29.
30. Feng, Y.; Wang, X. P.; Yang, S. G.; Wang, Y. J.; Zhang, X.; Du, X. T.; Sun, X. X.; Zhao, M.; Huang, L.; Liu, R. T. Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology, 2009, 30(6), 986-995.
31. Luo, Y.; Smith, J. V.; Paramasivam, V.; Burdick, A.; Curry, K. J.; Buford, J. P.; Khan, I.; Netzer, W. J.; Xu, H.; Butko, P. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. U.S.A., 2002, 99(19), 12197-12202.
32. Butterfield, D. A.; Castegna, A.; Lauderback, C. M.; Drake, J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging, 2002, 23(5), 655-664.
33. Arlt, S.; Beisiegel, U.; Kontush, A. Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease. Curr. Opin. Lipidol., 2002, 13(3), 289-294.
34. Sayre, L. M.; Zelasko, D. A.; Harris, P. L.; Perry, G.; Salomon, R. G.; Smith, M. A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem., 1997, 68(5), 2092-2097.
35. Gabbita, S. P.; Lovell, M. A.; Markesbery, W. R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem., 1998, 71(5), 2034-2040.
36. Prasad, M. R.; Lovell, M. A.; Yatin, M.; Dhillon, H.; Markesbery, W. R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res., 1998, 23(1), 81-88.
37. Smith, M. A.; Rudnicka-Nawrot, M.; Richey, P. L.; Praprotnik, D.; Mulvihill, P.; Miller, C. A.; Sayre, L. M.; Perry, G. Carbonylrelated posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J. Neurochem., 1995, 64(6), 2660-2666.
38. Nunomura, A.; Chiba, S.; Lippa, C. F.; Cras, P.; Kalaria, R. N.; Takeda, A.; Honda, K.; Smith, M. A.; Perry, G. Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiol. Dis., 2004, 17(1), 108-113.
39. Mecocci, P.; MacGarvey, U.; Beal, M. F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol., 1994, 36(5), 747-751.
40. Nunomura, A.; Perry, G.; Pappolla, M. A.; Wade, R.; Hirai, K.; Chiba, S.; Smith, M. A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci., 1999, 19(6), 1959-1964.
41. Zoccarato, F.; Cavallini, L.; Bortolami, S.; Alexandre, A. Succinate modulation of H2O2 release at NADH:ubiquinone oxidoreductase (Complex I) in brain mitochondria. Biochem. J., 2007, 406(1), 125 129.
42. St Pierre, J.; Buckingham, J. A.; Roebuck, S. J.; Brand, M. D. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J. Biol. Chem., 2002, 277(47), 44784-44790.
43. Fukui, K.; Onodera, K.; Shinkai, T.; Suzuki, S.; Urano, S. Impairment of learning and memory in rats caused by oxidative stress and aging, and changes in antioxidative defense systems. Ann. N. Y. Acad. Sci., 2001, 928 168-175.
44. Forster, M. J.; Dubey, A.; Dawson, K. M.; Stutts, W. A.; Lal, H.; Sohal, R. S. Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Proc. Natl. Acad. Sci. U.S.A., 1996, 93(10), 4765-4769.
45. Carney, J. M.; Starke-Reed, P. E.; Oliver, C. N.; Landum, R. W.; Cheng, M. S.; Wu, J. F.; Floyd, R. A. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone. Proc. Natl. Acad. Sci. U.S.A., 1991, 88(9), 3633-3636.
46. Klann, E.; Roberson, E. D.; Knapp, L. T.; Sweatt, J. D. A role for superoxide in protein kinase C activation and induction of longterm potentiation. J. Biol. Chem., 1998, 273(8), 4516-4522.
47. Klann, E. Cell-permeable scavengers of superoxide prevent longterm potentiation in hippocampal area CA1. J. Neurophysiol., 1998, 80(1), 452-457.
48. Knapp, L. T.; Klann, E. Potentiation of hippocampal synaptic transmission by superoxide requires the oxidative activation of protein kinase C. J. Neurosci., 2002, 22(3), 674-683.
49. Bliss, T. V.; Collingridge, G. L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 1993, 361(6407), 31-39.
50. Malenka, R. C.; Nicoll, R. A. Long-term potentiation--a decade of progress? Science, 1999, 285(5435), 1870-1874.
51. Haskew-Layton, R. E.; Mongin, A. A.; Kimelberg, H. K. Hydrogen peroxide potentiates volume-sensitive excitatory amino acid release via a mechanism involving Ca2+/calmodulin-dependent protein kinase II. J. Biol. Chem., 2005, 280(5), 3548-3554.
52. Kanterewicz, B. I.; Knapp, L. T.; Klann, E. Stimulation of p42 and p44 mitogen-activated protein kinases by reactive oxygen species and nitric oxide in hippocampus. J. Neurochem., 1998, 70(3), 1009-1016.
53. Kishida, K. T.; Pao, M.; Holland, S. M.; Klann, E. NADPH oxidase is required for NMDA receptor-dependent activation of ERK in hippocampal area CA1. J. Neurochem., 2005, 94(2), 299-306.
54. Zhang, L.; Jope, R. S. Oxidative stress differentially modulates phosphorylation of ERK, p38 and CREB induced by NGF or EGF in PC12 cells. Neurobiol. Aging, 1999, 20(3), 271-278.
55. Crossthwaite, A. J.; Hasan, S.; Williams, R. J. Hydrogen peroxidemediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurones: dependence on Ca(2+) and PI3-kinase. J. Neurochem., 2002, 80(1), 24-35.
56. Brigelius-Flohe, R. Tissue-specific functions of individual glutathione peroxidases. Free Radic. Biol. Med., 1999, 27(9-10), 951-965.
57. Halliwell, B. Drug antioxidant effects. A basis for drug selection? Drugs, 1991, 42(4), 569-605.
58. Butterfield, D. A.; Kanski, J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev., 2001, 122(9), 945-962.
59. Mecocci, P.; MacGarvey, U.; Kaufman, A. E.; Koontz, D.; Shoffner, J. M.; Wallace, D. C.; Beal, M. F. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol., 1993, 34(4), 609-616.
60. Harman, D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol., 1956, 11(3), 298-300.
61. Poon, H. F.; Calabrese, V.; Scapagnini, G.; Butterfield, D. A. Free radicals and brain aging. Clin. Geriatr. Med., 2004, 20(2), 329-359.
62. Ames, B. N.; Shigenaga, M. K.; Hagen, T. M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U.S. A, 1993, 90(17), 7915-7922.
63. Shulman, R. G.; Rothman, D. L.; Behar, K. L.; Hyder, F. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci., 2004, 27(8), 489-495.
64. Halliwell, B. Reactive oxygen species and the central nervous system. J. Neurochem., 1992, 59(5), 1609-1623.
65. Clarke, D. D.; Sokoloff, L. Circulation and energy metabolism of the brain, in Basic Neurochemistry: Moleular, Cellular and Medical Aspects, Siegel, G. J.; Albers, R. W.; Fisher, S. K.; Uhler, M. D., (eds); Raven Press: New York, 1999; pp. 638-669.
66. Hu, D.; Serrano, F.; Oury, T. D.; Klann, E. Aging-dependent alterations in synaptic plasticity and memory in mice that overexpress extracellular superoxide dismutase. J. Neurosci., 2006, 26(15), 3933-3941.
67. Thiels, E.; Urban, N. N.; Gonzalez-Burgos, G. R.; Kanterewicz, B. I.; Barrionuevo, G.; Chu, C. T.; Oury, T. D.; Klann, E. Impairment of long-term potentiation and associative memory in mice that overexpress extracellular superoxide dismutase. J. Neurosci., 2000, 20(20), 7631-7639.
68. Harrison, F. E.; Hosseini, A. H.; Dawes, S. M.; Weaver, S.; May, J. M. Ascorbic acid attenuates scopolamine-induced spatial learning deficits in the water maze. Behav. Brain Res., 2009, 205(2), 550-558.
69. Kiray, M.; Bagriyanik, H. A.; Pekcetin, C.; Ergur, B. U.; Uysal, N. Protective effects of deprenyl in transient cerebral ischemia in rats. Chin. J. Physiol., 2008, 51(5), 275-281.
70. Martins, R. N.; Harper, C. G.; Stokes, G. B.; Masters, C. L. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J. Neurochem., 1986, 46(4), 1042-1045.
71. Mecocci, P.; MacGarvey, U.; Beal, M. F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol., 1994, 36(5), 747-751.
72. Calingasan, N. Y.; Uchida, K.; Gibson, G. E. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem., 1999, 72(2), 751-756.
73. Bader Lange, M. L.; Cenini, G.; Piroddi, M.; Abdul, H. M.; Sultana, R.; Galli, F.; Memo, M.; Butterfield, D. A. Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol. Dis., 2008, 29(3), 456-464.
74. Pocernich, C. B.; Butterfield, D. A. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox. Res., 2003, 5(7), 515-520.
75. De Felice, F. G.; Velasco, P. T.; Lambert, M. P.; Viola, K.; Fernandez, S. J.; Ferreira, S. T.; Klein, W. L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem., 2007, 282(15), 11590-11601.
76. Marcus, D. L.; Strafaci, J. A.; Freedman, M. L. Differential neuronal expression of manganese superoxide dismutase in Alzheimer's disease. Med. Sci. Monit., 2006, 12(1), BR8-14.
77. Zemlan, F. P.; Thienhaus, O. J.; Bosmann, H. B. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. Brain Res., 1989, 476(1), 160-162.
78. West, M. J.; Kawas, C. H.; Martin, L. J.; Troncoso, J. C. The CA1 region of the human hippocampus is a hot spot in Alzheimer's disease. Ann. N. Y. Acad. Sci., 2000, 908 255-259.
79. Atwood, C. S.; Perry, G.; Zeng, H.; Kato, Y.; Jones, W. D.; Ling, K. Q.; Huang, X.; Moir, R. D.; Wang, D.; Sayre, L. M.; Smith, M. A.; Chen, S. G.; Bush, A. I. Copper mediates dityrosine crosslinking of Alzheimer's amyloid-beta. Biochemistry, 2004, 43(2), 560-568.
80. Barnham, K. J.; Haeffner, F.; Ciccotosto, G. D.; Curtain, C. C.; Tew, D.; Mavros, C.; Beyreuther, K.; Carrington, D.; Masters, C. L.; Cherny, R. A.; Cappai, R.; Bush, A. I. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease betaamyloid. FASEB J., 2004, 18(12), 1427-1429.
81. Siegel, S. J.; Bieschke, J.; Powers, E. T.; Kelly, J. W. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry, 2007, 46(6), 1503-1510.
82. Guglielmotto, M.; Aragno, M.; Autelli, R.; Giliberto, L.; Novo, E.; Colombatto, S.; Danni, O.; Parola, M.; Smith, M. A.; Perry, G.; Tamagno, E.; Tabaton, M. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J. Neurochem., 2009, 108(4), 1045-1056.
83. Li, F.; Calingasan, N. Y.; Yu, F.; Mauck, W. M.; Toidze, M.; Almeida, C. G.; Takahashi, R. H.; Carlson, G. A.; Flint, B. M.; Lin, M. T.; Gouras, G. K. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J. Neurochem., 2004, 89(5), 1308-1312.
84. Melov, S.; Adlard, P. A.; Morten, K.; Johnson, F.; Golden, T. R.; Hinerfeld, D.; Schilling, B.; Mavros, C.; Masters, C. L.; Volitakis, I.; Li, Q. X.; Laughton, K.; Hubbard, A.; Cherny, R. A.; Gibson, B.; Bush, A. I. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoSONE, 2007, 2(6), e536.
85. Su, B.; Wang, X.; Lee, H. G.; Tabaton, M.; Perry, G.; Smith, M. A.; Zhu, X. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci. Lett., 2010, 468(3), 267-271.
86. Crouch, P. J.; Harding, S. M.; White, A. R.; Camakaris, J.; Bush, A. I.; Masters, C. L. Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. Int. J. Biochem. Cell Biol., 2008, 40(2), 181-198.
87. Huang, X.; Cuajungco, M. P.; Atwood, C. S.; Hartshorn, M. A.; Tyndall, J. D.; Hanson, G. R.; Stokes, K. C.; Leopold, M.; Multhaup, G.; Goldstein, L. E.; Scarpa, R. C.; Saunders, A. J.; Lim, J.; Moir, R. D.; Glabe, C.; Bowden, E. F.; Masters, C. L.; Fairlie, D. P.; Tanzi, R. E.; Bush, A. I. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem., 1999, 274(52), 37111-37116.
88. Rival, T.; Page, R. M.; Chandraratna, D. S.; Sendall, T. J.; Ryder, E.; Liu, B.; Lewis, H.; Rosahl, T.; Hider, R.; Camargo, L. M.; Shearman, M. S.; Crowther, D. C.; Lomas, D. A. Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease. Eur. J. Neurosci., 2009, 29(7), 1335-1347.
89. Liu, G.; Men, P.; Perry, G.; Smith, M. A. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol. Biol., 2010, 610, 123-144.
90. Borchardt, T.; Camakaris, J.; Cappai, R.; Masters, C. L.; Beyreuther, K.; Multhaup, G. Copper inhibits beta-amyloid produc tion and stimulates the non-amyloidogenic pathway of amyloidprecursor protein secretion. Biochem. J., 1999, 344 Pt 2 461-467.
91. Bayer, T. A.; Schafer, S.; Simons, A.; Kemmling, A.; Kamer, T.; Tepest, R.; Eckert, A.; Schussel, K.; Eikenberg, O.; Sturchler Pierrat, C.; Abramowski, D.; Staufenbiel, M.; Multhaup, G. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc. Natl. Acad. Sci. U.S.A., 2003, 100(24), 14187-14192.
92. Bruce, A. J.; Malfroy, B.; Baudry, M. beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc. Natl. Acad. Sci. U.S.A., 1996, 93(6), 2312-2316.
93. Brewer, G. J.; Torricelli, J. R.; Lindsey, A. L.; Kunz, E. Z.; Neuman, A.; Fisher, D. R.; Joseph, J. A. Age-related toxicity of amyloid-beta associated with increased pERK and pCREB in primary hippocampal neurons: reversal by blueberry extract. J. Nutr. Biochem., 2010, 21(10), 991-8.
94. Lu, P.; Mamiya, T.; Lu, L. L.; Mouri, A.; Zou, L.; Nagai, T.; Hiramatsu, M.; Ikejima, T.; Nabeshima, T. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br. J. Pharmacol., 2009, 157(7), 1270-1277.
95. Liu, R.; Gao, M.; Qiang, G. F.; Zhang, T. T.; Lan, X.; Ying, J.; Du, G. H. The anti-amnesic effects of luteolin against amyloid beta(25 35) peptide-induced toxicity in mice involve the protection of neurovascular unit. Neuroscience, 2009, 162(4), 1232-1243.
96. Albani, D.; Polito, L.; Batelli, S.; De Mauro, S.; Fracasso, C.; Martelli, G.; Colombo, L.; Manzoni, C.; Salmona, M.; Caccia, S.; Negro, A.; Forloni, G. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J. Neurochem., 2009, 110(5), 1445-1456.
97. Bastianetto, S.; Ramassamy, C.; Dore, S.; Christen, Y.; Poirier, J.; Quirion, R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur. J. Neurosci., 2000, 12(6), 1882-1890.
98. Shi, C.; Zhao, L.; Zhu, B.; Li, Q.; Yew, D. T.; Yao, Z.; Xu, J. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptideinduced toxicity in SH-SY5Y cells. Chem. Biol. Interact., 2009, 181(1), 115-123.
99. Cuevas, E.; Limon, D.; Perez-Severiano, F.; Diaz, A.; Ortega, L.; Zenteno, E.; Guevara, J. Antioxidant effects of epicatechin on the hippocampal toxicity caused by amyloid-beta 25-35 in rats. Eur. J. Pharmacol., 2009, 616(1-3), 122-127.
100. Choi, S. J.; Jeong, C. H.; Choi, S. G.; Chun, J. Y.; Kim, Y. J.; Lee, J.; Shin, D. H.; Heo, H. J. Zeatin prevents amyloid beta-induced neurotoxicity and scopolamine-induced cognitive deficits. J. Med. Food, 2009, 12(2), 271-277.
101. Olcese, J. M.; Cao, C.; Mori, T.; Mamcarz, M. B.; Maxwell, A.; Runfeldt, M. J.; Wang, L.; Zhang, C.; Lin, X.; Zhang, G.; Arendash, G. W. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal. Res., 2009, 47(1), 82-96.
102. Hoppe, J. B.; Frozza, R. L.; Horn, A. P.; Comiran, R. A.; Bernardi, A.; Campos, M. M.; Battastini, A. M.; Salbego, C. Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta, tau and neuroinflammation. J. Pineal. Res., 2010, 48(3), 230-238.
103. Garcia-Matas, S.; de Vera, N.; Aznar, A. O.; Marimon, J. M.; Adell, A.; Planas, A. M.; Cristofol, R.; Sanfeliu, C. In Vitro and In Vivo activation of astrocytes by Amyloid-beta is potentiated by Pro-oxidant agents. J. Alzheimers. Dis., 2010, 20(1), 229-45.
104. Ye, J.; Meng, X.; Yan, C.; Wang, C. Effect of purple sweet potato anthocyanins on beta-amyloid-mediated PC-12 cells death by inhibition of oxidative stress. Neurochem. Res., 2010, 35(3), 357-365.
105. Oster, T.; Pillot, T. Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice. Biochim. Biophys. Acta, 2010, 1801(8), 791-8.
106. Lovell, M. A.; Xie, C.; Markesbery, W. R. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology, 1998, 51(6), 1562-1566.
107. Esposito, L.; Raber, J.; Kekonius, L.; Yan, F.; Yu, G. Q.; Bien-Ly, N.; Puolivali, J.; Scearce-Levie, K.; Masliah, E.; Mucke, L. Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J. Neurosci., 2006, 26(19), 5167-5179.
108. Du, H.; Guo, L.; Fang, F.; Chen, D.; Sosunov, A. A.; McKhann, G. M.; Yan, Y.; Wang, C.; Zhang, H.; Molkentin, J. D.; Gunn-Moore, F. J.; Vonsattel, J. P.; Arancio, O.; Chen, J. X.; Yan, S. D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med., 2008, 14(10), 1097-1105.
109. Serrano, F.; Chang, A.; Hernandez, C.; Pautler, R. G.; Sweatt, J. D.; Klann, E. NADPH oxidase mediates beta-amyloid peptideinduced activation of ERK in hippocampal organotypic cultures. Mol. Brain, 2009, 2(1), 31.
110. Huddleston, A. T.; Tang, W.; Takeshima, H.; Hamilton, S. L.; Klann, E. Superoxide-induced potentiation in the hippocampus requires activation of ryanodine receptor type 3 and ERK. J. Neurophysiol., 2008, 99(3), 1565-1571.
111. Kanterewicz, B. I.; Urban, N. N.; McMahon, D. B.; Norman, E. D.; Giffen, L. J.; Favata, M. F.; Scherle, P. A.; Trzskos, J. M.; Barrionuevo, G.; Klann, E. The extracellular signal-regulated kinase cascade is required for NMDA receptor-independent LTP in area CA1 but not area CA3 of the hippocampus. J. Neurosci., 2000, 20(9), 3057-3066.
112. Eccles, J. C. Mechanisms of long-term memory. J. Physiol. (Paris), 1986, 81(4), 312-317.
113. Ansari, M. A.; Scheff, S. W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J. Neuropathol. Exp. Neurol., 2010, 69(2), 155-167.
114. Joseph, J. A.; Denisova, N. A.; Arendash, G.; Gordon, M.; Diamond, D.; Shukitt-Hale, B.; Morgan, D. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr. Neurosci., 2003, 6(3), 153-162.
115. Tang, F.; Nag, S.; Shiu, S. Y.; Pang, S. F. The effects of melatonin and Ginkgo biloba extract on memory loss and choline acetyltransferase activities in the brain of rats infused intracerebroventricularly with beta-amyloid 1-40. Life Sci., 2002, 71(22), 2625-2631.
116. Sharma, M.; Briyal, S.; Gupta, Y. K. Effect of alpha lipoic acid, melatonin and trans resveratrol on intracerebroventricular streptozotocin induced spatial memory deficit in rats. Indian J. Physiol. Pharmacol., 2005, 49(4), 395-402.
117. Harrison, F. E.; Hosseini, A. H.; McDonald, M. P.; May, J. M. Vitamin C reduces spatial learning deficits in middle-aged and very old APP/PSEN1 transgenic and wild-type mice. Pharmacol. Biochem. Behav., 2009, 93(4), 443-450.
118. Harrison, F. E.; Allard, J.; Bixler, R.; Usoh, C.; Li, L.; May, J. M.; McDonald, M. P. Antioxidants and cognitive training interact to affect oxidative stress and memory in APP/PSEN1 mice. Nutr. Neurosci., 2009, 12(5), 203-218.
119. Yamada, K.; Tanaka, T.; Han, D.; Senzaki, K.; Kameyama, T.; Nabeshima, T. Protective effects of idebenone and alphatocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloidinduced neurotoxicity in vivo. Eur. J. Neurosci., 1999, 11(1), 83-90.
120. Rezai-Zadeh, K.; Arendash, G. W.; Hou, H.; Fernandez, F.; Jensen, M.; Runfeldt, M.; Shytle, R. D.; Tan, J. Green tea epigallocatechin 3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res., 2008, 1214, 177-187.
121. Ishrat, T.; Parveen, K.; Khan, M. M.; Khuwaja, G.; Khan, M. B.; Yousuf, S.; Ahmad, A.; Shrivastav, P.; Islam, F. Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin induced experimental dementia of Alzheimer's type. Brain Res., 2009, 1281, 117-127.
122. Allison, A. C.; Cacabelos, R.; Lombardi, V. R.; Alvarez, X. A.; Vigo, C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2001, 25(7), 1341-1357.
123. Wang, B.; Wang, X. M.; Fu, H.; Liu, G. X. Protective effects of Wu-Zi-Yan-Zong-Fang on amyloid beta-induced damage in vivo and in vitro. Yakugaku Zasshi, 2009, 129(8), 941-948.
124. Suchy, J.; Chan, A.; Shea, T. B. Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance. Nutr. Res, 2009, 29(1), 70-74.
125. Morris, M. C.; Evans, D. A.; Bienias, J. L.; Tangney, C. C.; Bennett, D. A.; Aggarwal, N.; Wilson, R. S.; Scherr, P. A. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA, 2002, 287(24), 3230 3237.
126. Perkins, A. J.; Hendrie, H. C.; Callahan, C. M.; Gao, S.; Unverzagt, F. W.; Xu, Y.; Hall, K. S.; Hui, S. L. Association of antioxidants with memory in a multiethnic elderly sample using the third national health and nutrition examination survey. Am. J. Epidemiol., 1999, 150(1), 37-44.
127. Masaki, K. H.; Losonczy, K. G.; Izmirlian, G.; Foley, D. J.; Ross, G. W.; Petrovitch, H.; Havlik, R.; White, L. R. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology, 2000, 54(6), 1265-1272.
128. Grodstein, F.; Chen, J.; Willett, W. C. High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am. J. Clin. Nutr., 2003, 77(4), 975-984.
129. Engelhart, M. J.; Geerlings, M. I.; Ruitenberg, A.; van Swieten, J. C.; Hofman, A.; Witteman, J. C.; Breteler, M. M. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA, 2002, 287(24), 3223-3229.
130. Engelhart, M. J.; Ruitenberg, A.; Meijer, J.; Kiliaan, A.; van Swieten, J. C.; Hofman, A.; Witteman, J. C.; Breteler, M. M. Plasma levels of antioxidants are not associated with Alzheimer's disease or cognitive decline. Dement. Geriatr. Cogn. Disord., 2005, 19(2-3), 134-139.
131. Fillenbaum, G. G.; Kuchibhatla, M. N.; Hanlon, J. T.; Artz, M. B.; Pieper, C. F.; Schmader, K. E.; Dysken, M. W.; Gray, S. L. Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann. Pharmacother., 2005, 39(12), 2009-2014.
132. Gray, S. L.; Anderson, M. L.; Crane, P. K.; Breitner, J. C.; McCormick, W.; Bowen, J. D.; Teri, L.; Larson, E. Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. J. Am. Geriatr. Soc., 2008, 56(2), 291-295.
133. Laurin, D.; Masaki, K. H.; Foley, D. J.; White, L. R.; Launer, L. J. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am. J. Epidemiol., 2004, 159(10), 959-967.
134. Luchsinger, J. A.; Tang, M. X.; Shea, S.; Mayeux, R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch. Neurol., 2003, 60(2), 203-208.
135. Maxwell, C. J.; Hicks, M. S.; Hogan, D. B.; Basran, J.; Ebly, E. M. Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement. Geriatr. Cogn. Disord., 2005, 20(1), 45-51.
136. Morris, M. C.; Evans, D. A.; Bienias, J. L.; Tangney, C. C.; Wilson, R. S. Vitamin E and cognitive decline in older persons. Arch. Neurol., 2002, 59(7), 1125-1132.
137. Petersen, R. C.; Thomas, R. G.; Grundman, M.; Bennett, D.; Doody, R.; Ferris, S.; Galasko, D.; Jin, S.; Kaye, J.; Levey, A.; Pfeiffer, E.; Sano, M.; van Dyck, C. H.; Thal, L. J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med., 2005, 352(23), 2379-2388.
138. Sano, M.; Ernesto, C.; Thomas, R. G.; Klauber, M. R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, C. W.; Pfeiffer, E.; Schneider, L. S.; Thal, L. J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med., 1997, 336(17), 1216-1222.
139. Zandi, P. P.; Anthony, J. C.; Khachaturian, A. S.; Stone, S. V.; Gustafson, D.; Tschanz, J. T.; Norton, M. C.; Welsh-Bohmer, K. A.; Breitner, J. C. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol, 2004, 61(1), 82-88.
140. Antonenko, Y. N.; Avetisyan, A. V.; Bakeeva, L. E.; Chernyak, B. V.; Chertkov, V. A.; Domnina, L. V.; Ivanova, O. Y.; Izyumov, D. S.; Khailova, L. S.; Klishin, S. S.; Korshunova, G. A.; Lyamzaev, K. G.; Muntyan, M. S.; Nepryakhina, O. K.; Pashkovskaya, A. A.; Pletjushkina, O. Y.; Pustovidko, A. V.; Roginsky, V. A.; Rokitskaya, T. I.; Ruuge, E. K.; Saprunova, V. B.; Severina, I. I.; Simonyan, R. A.; Skulachev, I. V.; Skulachev, M. V.; Sumbatyan, N. V.; Sviryaeva, I. V.; Tashlitsky, V. N.; Vassiliev, J. M.; Vyssokikh, M. Y.; Yaguzhinsky, L. S.; Zamyatnin, A. A., Jr.; Skulachev, V. P. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: synthesis and in vitro studies. Biochemistry (Mosc.), 2008, 73(12), 1273-1287.
141. Skulachev, V. P.; Anisimov, V. N.; Antonenko, Y. N.; Bakeeva, L. E.; Chernyak, B. V.; Erichev, V. P.; Filenko, O. F.; Kalinina, N. I.; Kapelko, V. I.; Kolosova, N. G.; Kopnin, B. P.; Korshunova, G. A.; Lichinitser, M. R.; Obukhova, L. A.; Pasyukova, E. G.; Pisarenko, O. I.; Roginsky, V. A.; Ruuge, E. K.; Senin, I. I.; Severina, I. I.; Skulachev, M. V.; Spivak, I. M.; Tashlitsky, V. N.; Tkachuk, V. A.; Vyssokikh, M. Y.; Yaguzhinsky, L. S.; Zorov, D. B. An attempt to prevent senescence: a mitochondrial approach. Biochim. Biophys. Acta, 2009, 1787(5), 437-461.
142. Anisimov, V. N.; Bakeeva, L. E.; Egormin, P. A.; Filenko, O. F.; Isakova, E. F.; Manskikh, V. N.; Mikhelson, V. M.; Panteleeva, A. A.; Pasyukova, E. G.; Pilipenko, D. I.; Piskunova, T. S.; Popovich, I. G.; Roshchina, N. V.; Rybina, O. Y.; Saprunova, V. B.; Samoylova, T. A.; Semenchenko, A. V.; Skulachev, M. V.; Spivak, I. M.; Tsybul'ko, E. A.; Tyndyk, M. L.; Vyssokikh, M. Y.; Yurova, M. N.; Zabezhinsky, M. A.; Skulachev, V. P. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 5. SkQ1 prolongs lifespan and prevents development of traits of senescence. Biochemistry (Mosc.), 2008, 73(12), 1329-1342.
143. Neroev, V. V.; Archipova, M. M.; Bakeeva, L. E.; Fursova, A. Z.; Grigorian, E. N.; Grishanova, A. Y.; Iomdina, E. N.; Ivashchenko, Z.; Katargina, L. A.; Khoroshilova-Maslova, I. P.; Kilina, O. V.; Kolosova, N. G.; Kopenkin, E. P.; Korshunov, S. S.; Kovaleva, N. A.; Novikova, Y. P.; Philippov, P. P.; Pilipenko, D. I.; Robustova, O. V.; Saprunova, V. B.; Senin, I. I.; Skulachev, M. V.; Sotnikova, L. F.; Stefanova, N. A.; Tikhomirova, N. K.; Tsapenko, I. V.; Shchipanova, A. I.; Zinovkin, R. A.; Skulachev, V. P. Mitochondria targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 4. Age-related eye disease. SkQ1 returns vision to blind animals. Biochemistry (Mosc.), 2008, 73(12), 1317-1328.
144. Agapova, L. S.; Chernyak, B. V.; Domnina, L. V.; Dugina, V. B.; Efimenko, A. Y.; Fetisova, E. K.; Ivanova, O. Y.; Kalinina, N. I.; Khromova, N. V.; Kopnin, B. P.; Kopnin, P. B.; Korotetskaya, M. V.; Lichinitser, M. R.; Lukashev, A. L.; Pletjushkina, O. Y.; Popova, E. N.; Skulachev, M. V.; Shagieva, G. S.; Stepanova, E. V.; Titova, E. V.; Tkachuk, V. A.; Vasiliev, J. M.; Skulachev, V. P. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 3. Inhibitory effect of SkQ1 on tumor development from p53-deficient cells. Biochemistry (Mosc.), 2008, 73(12), 1300-1316.
145. Bakeeva, L. E.; Barskov, I. V.; Egorov, M. V.; Isaev, N. K.; Kapelko, V. I.; Kazachenko, A. V.; Kirpatovsky, V. I.; Kozlovsky, S. V.; Lakomkin, V. L.; Levina, S. B.; Pisarenko, O. I.; Plotnikov, E. Y.; Saprunova, V. B.; Serebryakova, L. I.; Skulachev, M. V.; Stelmashook, E. V.; Studneva, I. M.; Tskitishvili, O. V.; Vasilyeva, A. K.; Victorov, I. V.; Zorov, D. B.; Skulachev, V. P. Mitochondria targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 2. Treatment of some ROS and agerelated diseases (heart arrhythmia, heart infarctions, kidney ischemia, and stroke). Biochemistry (Mosc.), 2008, 73(12), 1288-1299.
146. Antonenko, Y. N.; Roginsky, V. A.; Pashkovskaya, A. A.; Rokitskaya, T. I.; Kotova, E. A.; Zaspa, A. A.; Chernyak, B. V.; Skulachev, V. P. Protective effects of mitochondria-targeted anti oxidant SkQ in aqueous and lipid membrane environments. J. Membr. Biol., 2008, 222(3), 141-149.
147. Stokin, G. B.; Lillo, C.; Falzone, T. L.; Brusch, R. G.; Rockenstein, E.; Mount, S. L.; Raman, R.; Davies, P.; Masliah, E.; Williams, D. S.; Goldstein, L. S. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science, 2005, 307(5713), 1282-1288.
148. Gong, C. X.; Iqbal, K. Hyperphosphorylation of microtubuleassociated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem., 2008, 15(23), 2321-2328.
149. Higuchi, M.; Lee, V. M.; Trojanowski, J. Q. Tau and axonopathy in neurodegenerative disorders. Neuromol. Med., 2002, 2(2), 131-150.
150. Shah, S. B.; Nolan, R.; Davis, E.; Stokin, G. B.; Niesman, I.; Canto, I.; Glabe, C.; Goldstein, L. S. Examination of potential mechanisms of amyloid-induced defects in neuronal transport. Neurobiol. Dis., 2009, 36(1), 11-25.
151. Folwell, J.; Cowan, C. M.; Ubhi, K. K.; Shiabh, H.; Newman, T. A.; Shepherd, D.; Mudher, A. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease. Exper. Neurol., 2009, 223(2), 401-9.
152. Mitsuyama, F.; Futatsugi, Y.; Okuya, M.; Karagiozov, K.; Peev, N.; Kato, Y.; Kanno, T.; Sano, H.; Koide, T. Amyloid beta: a putative intra-spinal microtubule-depolymerizer to induce synapseloss or dentritic spine shortening in Alzheimer's disease. Ital. J. Anat. Embryol., 2009, 114(2-3), 109-120.
153. Roberson, E. D.; Scearce-Levie, K.; Palop, J. J.; Yan, F.; Cheng, I. H.; Wu, T.; Gerstein, H.; Yu, G. Q.; Mucke, L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science, 2007, 316(5825), 750-754.
154. Kulic, L.; Wollmer, M. A.; Rhein, V.; Pagani, L.; Kuehnle, K.; Cattepoel, S.; Tracy, J.; Eckert, A.; Nitsch, R. M. Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration. Neurobiol. Aging, 2009 [Epub ahead of print]. PMID: 20479943.
155. Massaad, C. A.; Amin, S. K.; Hu, L.; Mei, Y.; Klann, E.; Pautler, R. G. Overexpression of SOD-2 ameliorates cerebral blood flow and reverses axonal transport deficits in a mouse model of Alzheimer's disease. PLoS Biol., 2010, 5(5), e10561.
156. Tremblay, M. A.; Acker, C. M.; Davies, P. Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J. Alzheimers Dis., 2010, 19(2), 721-733.
157. Lebouvier, T.; Scales, T. M.; Williamson, R.; Noble, W.; Duyckaerts, C.; Hanger, D. P.; Reynolds, C. H.; Anderton, B. H.; Derkinderen, P. The microtubule-associated protein tau is also phosphorylated on tyrosine. J. Alzheimers Dis., 2009, 18(1), 1-9.
158. Cao, C.; Ren, X.; Kharbanda, S.; Koleske, A.; Prasad, K. V.; Kufe, D. The ARG tyrosine kinase interacts with Siva-1 in the apoptotic response to oxidative stress. J. Biol. Chem., 2001, 276(15), 11465 11468.
159. Calhoun, M. E.; Burgermeister, P.; Phinney, A. L.; Stalder, M.; Tolnay, M.; Wiederhold, K. H.; Abramowski, D.; Sturchler-Pierrat, C.; Sommer, B.; Staufenbiel, M.; Jucker, M. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. U.S.A., 1999, 96(24), 14088-14093.
160. Christie, R.; Yamada, M.; Moskowitz, M.; Hyman, B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am. J. Pathol., 2001, 158(3), 1065-1071.
161. Kalaria, R. N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging, 2000, 21(2), 321-330.
162. Iadecola, C. Atherosclerosis and neurodegeneration: unexpected conspirators in Alzheimer's dementia. Arterioscler. Thromb. Vasc. Biol., 2003, 23(11), 1951-1953.
163. Casserly, I.; Topol, E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet, 2004, 363(9415), 1139-1146.
164. Tagliavini, F.; Ghiso, J.; Timmers, W. F.; Giaccone, G.; Bugiani, O.; Frangione, B. Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls. Lab. Invest., 1990, 62(6), 761-767.
165. Kawai, M.; Kalaria, R. N.; Harik, S. I.; Perry, G. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am. J. Pathol., 1990, 137(6), 1435-1446.
166. Crawford, J. G. Alzheimer's disease risk factors as related to cerebral blood flow: additional evidence. Med. Hypotheses, 1998, 50(1), 25-36.
167. Suo, Z.; Su, G.; Placzek, A.; Kundtz, A.; Humphrey, J.; Crawford, F.; Mullan, M. A beta vasoactivity in vivo. Ann. N. Y. Acad. Sci., 2000, 903 156-163.
168. Perry, G.; Smith, M. A.; McCann, C. E.; Siedlak, S. L.; Jones, P. K.; Friedland, R. P. Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Res., 1998, 791(1-2), 63-66.
169. Lum, H.; Roebuck, K. A. Oxidant stress and endothelial cell dysfunction. Am. J. Physiol. Cell Physiol., 2001, 280(4), C719-C741.
170. Faraci, F. M.; Heistad, D. D. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol. Rev., 1998, 78(1), 53-97.
171. Marletta, M. A. Nitric oxide synthase structure and mechanism. J. Biol. Chem., 1993, 268(17), 12231-12234.
172. Moncada, S.; Palmer, R. M.; Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 1991, 43(2), 109-142.
173. Sessa, W. C. eNOS at a glance. J. Cell Sci., 2004, 117(Pt 12), 2427-2429.
174. Kone, B. C.; Kuncewicz, T.; Zhang, W.; Yu, Z. Y. Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am. J. Physiol. Renal. Physiol., 2003, 285(2), F178-F190.
175. Beckman, J. S.; Koppenol, W. H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol., 1996, 271(5 Pt 1), C1424-C1437.
176. Naseem, K. M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med., 2005, 26(1-2), 33-65.
177. Maxwell, A. J. Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric Oxide, 2002, 6(2), 101-124.
178. Luth, H. J.; Holzer, M.; Gartner, U.; Staufenbiel, M.; Arendt, T. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res., 2001, 913(1), 57-67.
179. Luth, H. J.; Munch, G.; Arendt, T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res., 2002, 953(1-2), 135-143.
180. Aziz, A. A.; Leeming, R. J.; Blair, J. A. Tetrahydrobiopterin metabolism in senile dementia of Alzheimer type. J. Neurol. Neurosurg. Psychiatry, 1983, 46(5), 410-413.
181. Barford, P. A.; Blair, J. A.; Eggar, C.; Hamon, C.; Morar, C.; Whitburn, S. B. Tetrahydrobiopterin metabolism in the temporal lobe of patients dying with senile dementia of Alzheimer type. J. Neurol. Neurosurg. Psychiatry, 1984, 47(7), 736-738.
182. Xia, Y.; Tsai, A. L.; Berka, V.; Zweier, J. L. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulindependent and tetrahydrobiopterin regulatory process. J. Biol. Chem., 1998, 273(40), 25804-25808.
183. Vasquez-Vivar, J.; Kalyanaraman, B.; Martasek, P.; Hogg, N.; Masters, B. S.; Karoui, H.; Tordo, P.; Pritchard, K. A., Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(16), 9220-9225.
184. Fulton, D.; Gratton, J. P.; McCabe, T. J.; Fontana, J.; Fujio, Y.; Walsh, K.; Franke, T. F.; Papapetropoulos, A.; Sessa, W. C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature, 1999, 399(6736), 597-601.
185. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A. M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 1999, 399(6736), 601-605.
186. Chen, C. A.; Druhan, L. J.; Varadharaj, S.; Chen, Y. R.; Zweier, J. L. Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme. J. Biol. Chem., 2008, 283(40), 27038-27047.
187. Nicolakakis, N.; Aboulkassim, T.; Ongali, B.; Lecrux, C.; Fernandes, P.; Rosa-Neto, P.; Tong, X. K.; Hamel, E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferatoractivated receptor gamma agonist. J. Neurosci., 2008, 28(37), 9287-9296.
188. Wenzel, P.; Schuhmacher, S.; Kienhofer, J.; Muller, J.; Hortmann, M.; Oelze, M.; Schulz, E.; Treiber, N.; Kawamoto, T.; Scharffetter Kochanek, K.; Munzel, T.; Burkle, A.; Bachschmid, M. M.; Daiber, A. Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc. Res., 2008, 80(2), 280-289.
189. Park, L.; Anrather, J.; Girouard, H.; Zhou, P.; Iadecola, C. Nox2 derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J. Cereb. Blood Flow Metab., 2007, 27(12), 1908-1918.
190. Shin, H. K.; Jones, P. B.; Garcia-Alloza, M.; Borrelli, L.; Greenberg, S. M.; Bacskai, B. J.; Frosch, M. P.; Hyman, B. T.; Moskowitz, M. A.; Ayata, C. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain, 2007, 130(Pt 9), 2310-2319.
191. Zhu, X.; Smith, M. A.; Honda, K.; Aliev, G.; Moreira, P. I.; Nunomura, A.; Casadesus, G.; Harris, P. L.; Siedlak, S. L.; Perry, G. Vascular oxidative stress in Alzheimer disease. J. Neurol. Sci., 2007, 257(1-2), 240-246.